On the way towards the Sustainable Development Goal (SDG) for health, Europe has one important battle to take on: reducing the proportion of those living with undiagnosed HIV and viral hepatitis. Current status in the EU/EEA: one in seven people living with HIV are unaware of their infection, up to four out of 5 people living with hepatitis B and three out of four people with hepatitis C infection have not yet been diagnosed.
The Flu Awareness Week is marked across the WHO European Region every year in October. It aims to raise awareness of the importance of vaccination for people’s health and well-being and to increase the uptake of seasonal influenza vaccination of people with underlying risk factors.
Organized by:World Health Organization (WHO) - Regional office for Europe
This estimate on the “PrEP gap” in Europe was published in a paper in Eurosurveillance stating that 500 000 men who have sex with men in the European Union currently cannot access HIV pre-exposure prophylaxis (PrEP), despite being very likely to use it.
On September 2019, WHO has agreed on the recommended composition of the quadrivalent and trivalent influenza vaccines for the southern hemisphere 2020 influenza season.
Targeted testing is an essential element of any strategy to eliminate viral hepatitis across the countries in the European Union and European Economic Area. Some preliminary monitoring results on the response to hepatitis B and C presented around World Hepatitis Day show that diagnosing chronic infections is still a challenge in the EU/EEA.
The number of syphilis cases has been consistently going up across Europe since 2010, mostly affecting men who have sex with men living in urban areas. In 2017, notification rates reached an all-time high in the EU/EEA countries with more than 33 000 reported cases. An in-depth ECDC study published today describes the factors behind this increase and outlines the evidence-based options for public health control of syphilis, including case finding and management as well as educational activities.
In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008.
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
Following a decline in notification rates in 2016, the number of gonorrhoea cases has gone up by 17% across the reporting EU/EEA countries with more than 89 000 confirmed diagnoses in 2017 – more than 240 cases a day.